SillaJen

SillaJen EBIT Margin

The EBIT Margin (Operating Margin) of SillaJen (215600.KQ) as of Nov 3, 2026 is -285.30 %. In the previous year, EBIT Margin (Operating Margin) was -716.20 % — a change of -60.16% (higher).

EBIT Margin

-285.30 %

YoY

-60.16%

Last updated:

EBIT Margin (Operating Margin) of SillaJen is 2025 -285.30 % . EBIT Margin (Operating Margin) of SillaJen was 2024 -716.20 % . It decreases by -60.16% higher compared to the previous year.

SillaJen's operating (EBIT) margin stands at -285.3%, up from -7,753.8% several years earlier.

The SillaJen EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2017
-737.35 KRW
Jan 1, 2018
-768.66 KRW
Jan 1, 2020
-2,075.86 KRW
Jan 1, 2021
-7,753.75 KRW
Jan 1, 2022
-488.71 KRW
Jan 1, 2023
-541.78 KRW
Jan 1, 2024
-716.20 KRW
Jan 1, 2025
-285.30 KRW
The SillaJen EBIT Margin history
YEAREBIT MarginYoY
-285.30 %-60.16%
-716.20 %+32.19%
-541.78 %+10.86%
-488.71 %-93.70%
-7,753.75 %+273.52%
-2,075.86 %+170.06%
-768.66 %+4.25%
-737.35 %-16.66%
-884.76 %-32.65%
-1,313.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SillaJen Stock analysis

What does SillaJen do? SillaJen, Inc. generates revenue through the development and commercialization of oncolytic immunotherapeutics, primarily focusing on viral therapies for cancer treatment. The company's major product, Pexa-Vec, is currently in a global Phase 3 clinical trial for liver cancer treatment, while additional oncolytic virus immunotherapeutics such as SJ-102, SJ-103, SJ-815, JX-929, JX-930, and JX-963 are also part of its portfolio. These products target oncology segments, particularly liver cancer, and are developed for potential use in clinical settings. SillaJen's revenue streams are derived from the progression of these therapies through clinical trials and eventual market entry, with Pexa-Vec representing the most advanced product in its pipeline. The company's product portfolio includes multiple oncolytic virus immunotherapeutics, each identified by specific codes such as SJ-102, SJ-103, SJ-815, JX-929, JX-930, and JX-963, which are designed for various cancer treatments. Pexa-Vec, the lead candidate, is in Phase 3 trials for liver cancer, indicating a focus on advanced-stage oncology solutions. These products are developed for pharmaceutical and biotech companies seeking innovative cancer therapies, with the primary target being liver cancer patients in clinical trials. SillaJen's business model relies on the successful advancement of these clinical trials to secure partnerships or direct sales in the oncology market. SillaJen's revenue is tied to the clinical development and potential commercialization of its oncolytic virus immunotherapeutics. The company's pipeline includes Pexa-Vec, which is in a global Phase 3 clinical trial for liver cancer, and other products like SJ-102, SJ-103, SJ-815, JX-929, JX-930, and JX-963, which are part of its broader portfolio. These products are intended for use in oncology treatments, particularly targeting liver cancer. The company's focus on advancing these therapies through clinical stages positions it to generate revenue through partnerships or direct sales once the products are approved and marketed. SillaJen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SillaJen stock

EBIT Margin (Operating Margin) of SillaJen is -285.30 % in 2025.

EBIT Margin (Operating Margin) of SillaJen changed from -716.20 % to -285.30 %, representing a -60.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) SillaJen since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s SillaJen with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — SillaJen

All Key Metrics — SillaJen